# Teva autoimmune antibody notches ph. 2 win in celiac disease

> **Open Intelligence Dossier** · First detected: 2026-09-03 07:07 UTC · Category: Business

## Executive Summary
Teva's experimental antibody TEV-408 meets its primary goal in a mid-stage celiac disease trial.

## Intelligence Brief
Recent reporting across financial and pharmaceutical news outlets indicates that Teva has achieved a significant clinical milestone. Specifically, the company&amp;#039;s experimental immune disorder drug, known as TEV-408 or anti-IL-15, successfully hit its key Phase IIa endpoint in a celiac disease study. Outlets such as Reuters, FirstWord Pharma, Endpoints News, Fierce Biotech, Yahoo Finance, Investing.com India, TradingView, and WKZO have covered the development. According to these sources, the mid-stage trial results demonstrated that the treatment met its main goal, prompting immediate market attention and reporting on why Teva stock was surging. Coverage places heavy emphasis on the competitive dynamics of the pharmaceutical sector, noting that the trial success heats up the IL-15 drug market.


Endpoints News explicitly highlights the single-shot success aspect of the trial, while Fierce Biotech characterizes the outcome as a phase 2 win for the autoimmune antibody. Yahoo Finance frames the trial announcement alongside unrelated industry developments, such as a patent dispute settlement between BioMarin and Ascendis. The wide distribution of the story across general financial platforms like Yahoo Finance and TradingView alongside specialized trade publications like FirstWord Pharma and Fierce Biotech underscores the broad commercial interest in the trial outcome. The context provided by the coverage centers on the therapeutic category and the specific target mechanism, namely anti-IL-15, aimed at treating celiac disease. Celiac disease represents a major unmet medical need in the immunology space, which explains why mid-stage clinical trial results for a potential treatment can drive substantial market movement and investor interest in Teva Pharma stock.


While the available headlines establish that the drug met its main goal in the Phase IIa study, the current coverage does not yet specify the detailed statistical breakdown of the trial data, the exact safety profile observed, or the specific timeline for subsequent late-stage clinical development. Future coverage will likely focus on how Teva plans to advance the drug into subsequent phases of clinical testing and whether additional data from the Phase IIa trial will be presented at upcoming medical meetings. Stakeholders and market observers will also be watching to see if competitors in the IL-15 market adjust their development strategies in response to Teva&amp;#039;s mid-stage success. The outlets that reported on this initial phase 2 win are expected to follow up as further regulatory disclosures, financial reports, or clinical trial updates become available from the company.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| finance.yahoo.com | Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxNQmp0UDFMNUR0UlAwazRVVGQxQ3JWWktrM200TlpBalJHNHgyZDVySHJZS2tOcFRSQUdtS0d5QjlpY1F1RzFtbnNKWTFIOG9aNERLZlVVYmdtUlAzZ1Rqc3lxQTdfUFFNS1lOM05jSi1wbnRxdWZ5YWUxS3o1aG9pM2gtc3NramJMZEE?oc=5) |
| FirstWord Pharma | Teva's anti–IL-15 shows positive mid-stage results in coeliac disease | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5FUGJWRTFoa2xRTDNZaURCcmNadzhFenhoX3NXZUhRNTZCOFp6SV8xSjhJZWhmcmxsSDJjdmR0Yzhzd09jWXlPNC1RUmplRFA2ajJB?oc=5) |
| Endpoints News | Teva reports a single-shot success in celiac disease, heating the IL-15 market | [Source Link](https://news.google.com/rss/articles/CBMiiwFBVV95cUxNMDlmQzB0S1FMcTQwUERyTGlxZTFjeHNPUGZHLXBtU29xOW9va3ZRcVQ2Q1V5LXpvRGNHaE9kVE5ZbERTcUlHdUZiV2h4ejR5cm92ZGdPQ0l0LS1ERXdrX1hUY3lyOHM3MFVmZjg3QnlOb1BUOHp0NHgya2NyVGNYbEF1RnRpWnJoQk1J?oc=5) |
| Reuters | Teva's immune disorder drug meets main goal in mid-stage trial | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxOcVFEcmljY2dUX2Nob3I4bE1XdTlBblBuRU8ta0NVbTNNYjg3T0U0QmlnWGhJc3ZtQi1RejgtSko0QXNPTUhEWV9zYUlqSEJ2alV3LVZCX3BvaFA2MWZjYTNCSFEwWXhEUGpUclE1RHB4VGNtYWl0ekpISmVYenBTbTdyb1dnR2o1Q2RxS29adGVHa05NT0tWak1JNk12aE9QVTFidXIyMFRpUmZPM1ZaVDlSZDRXWHNVRS1Hc3VJREFwTUJKaFB6d2Zn?oc=5) |
| tradingview.com | Teva's immune disorder drug meets main goal in mid-stage trial | [Source Link](https://news.google.com/rss/articles/CBMizAFBVV95cUxORWF6R0ZqRmNMaXc1Q04yZVczUEpLY0t1dWlLdU5IRU1zWk1JYzVzcXVXVWRPRmVNbmVTNW1QT3hvdjdCM2UtSFc3ODNZVHBRMGhGQkFDOWpYb0pxTUtNSkJyVFpXd1Bub1VSWFpEay1SMUF5eEkyUmx0UnV1dkJPcENRLUlsYkpBUWpmbXhRVFlmVXVudnhVR0JBMUVwQjdDM3hsd3ZYN3ZaSWdhM2VnTDRfQVZESUdDMTd5UWFpVU40ck5oRUlwaEtZRVo?oc=5) |
| Yahoo Finance | Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxQRWFUY0VBbkp4UDU3WmpKWUY1eEgxaEg4LVQ2U3kzTnBDZVIwLVhYSW5NYUd2WlVGeXBfY2tveVh5VDg4cTZTV0ZNQ0FZeUdUVFdhLWh2OWVYdEpJNXZSZGd2V0tpNDhQMlJjMHpFWE84dlV3UmVxcEd4NTAzbVpFS2p0bkNtNmF2QkY2QUpDVzJ1S2RvdXIwbg?oc=5) |
| Investing.com India | Why is Teva Pharma stock surging today? | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxNUDVmNDRnWjFvcThTS3VnRl9FeGJDblZ0RXgyUVhqWmczY2Y5UkhiNTVqaThhQmdEYV9MZURUTEp6M2pudjI2RXZ2T1RTQnoxeTd1bHhyNjIwZ1lUZDYxSGV6V2tGeTdGSjZsZnQ0OTAyVFQ2SEo0UGtsRDhjdXVnTktEaFFTeWNzSkd6YTJhS3luNVpER0dod2x0ZFNhbThl?oc=5) |
| WKZO | Teva’s immune disorder drug meets main goal in mid-stage trial | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxQU2hMN2k5MG9zMFJpeW5wQ2JmdXdlMTFpc0F4d0pteGZ5czdjUEptQ0xFWDN6R1hmeGxjMFR1dUVCUFU3Ni1aRXRlbHdOTWwzRkhrYWkwc29aMVN4ajVnZmEtdU1HQU8ySU5Qd24xSFo4UmRhY2FuamFIOE01TVVreVRicHR2N1pJMS1qNTJ6dDNrczZ6?oc=5) |
| Fierce Biotech | Teva autoimmune antibody notches ph. 2 win in celiac disease | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNVWhQU3l4RGJJOUVKUEQ2QWQ0SGt1YVZyVnVOUUc4eDlvVlF0c1hNeFVVbTRSNjVJN1AwcU9wTmpFWFg1S0t3d1VqZWkwNmhGUGMwQlNnSHpiTzh1XzFaM2daRWItV3VIdmxYM2ZPaUNtZFBNTWw2UFc2aFZuaGJ4ZERBbnZ1MS1ZUGEzRWxjaExvQTh4RUdrOHZR?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-03/teva-autoimmune-antibody-notches-ph-2-win-in-celiac-disease*
